Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Topotecan Hydrochloride

FDA-approved product (injectable, injection), marketed as Hycamtin, Topotecan, Topotecan Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Topotecan Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Carcinoma
  • Cervical adenocarcinoma
  • Cervical cancer
  • Cervical carcinoma
  • Ovarian cancer
  • Ovarian neoplasm
  • Small cell carcinoma
  • Small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Topoisomerase 1 (top1) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Topotecan Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Topotecan Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer

    NCT07797153 · start 2026-09

    Registered record
    Registry ID
    NCT07797153
    Conditions
    Recurrent or Metastatic Cervical Cancer
    Interventions
    JSKN033; Docetaxel; Topotecan; Gemcitabine (GEM); Pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2029-12
    Enrolment
    368

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent or Metastatic Cervical Cancer
    InterventionJSKN033; Docetaxel; Topotecan; Gemcitabine (GEM) +1 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • Chronic CED of TPT for Recurrent Malignant Glioma

    NCT06666712 · start 2026-06-12

    Registered record
    Registry ID
    NCT06666712
    Conditions
    Brain Tumor, Recurrent; Malignant Glioma (WHO Grade III or IV); IDH1/IDH2 Mutation
    Interventions
    Topotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-06-12
    Completion
    2028-01
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain Tumor, Recurrent; Malignant Glioma (WHO Grade III or IV); IDH1/IDH2 Mutation
    InterventionTopotecan
    PhasePhase 1
    Registry statusRecruiting

  • Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

    NCT07194044 · start 2026-02-05

    Registered record
    Registry ID
    NCT07194044
    Conditions
    Metastatic Ewing Sarcoma
    Interventions
    Vincristine; Doxorubicin; Cyclophosphamide; Ifosfamide; Actinomycin; Irinotecan; Cabozantinib; Topotecan; Temozolomide; Etoposide; Liposomal doxorubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-02-05
    Completion
    2030-10
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Ewing Sarcoma
    InterventionVincristine; Doxorubicin; Cyclophosphamide; Ifosfamide +7 more
    PhasePhase 1
    Registry statusRecruiting

  • An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing

    NCT07141771 · start 2025-12-31

    Registered record
    Registry ID
    NCT07141771
    Conditions
    SCLC, Extensive Stage
    Interventions
    Serplulimab; Fluzoparib; Topotecan/Irinotecan/Paclitaxel/Temozolomide; Etoposide/Carboplatin/Cisplatin; Lurbinectedin; Temozolomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-12-31
    Completion
    2030-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSCLC, Extensive Stage
    InterventionSerplulimab; Fluzoparib; Topotecan/Irinotecan/Paclitaxel/Temozolomide; Etoposide/Carboplatin/Cisplatin +2 more
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

    NCT07189455 · start 2025-12-12

    Registered record
    Registry ID
    NCT07189455
    Conditions
    Small-cell Lung Cancer
    Interventions
    ZG006; Topotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-12-12
    Completion
    2028-12
    Enrolment
    420

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall-cell Lung Cancer
    InterventionZG006; Topotecan
    PhasePhase 3
    Registry statusRecruiting

  • An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

    NCT07371663 · start 2025-12-03

    Registered record
    Registry ID
    NCT07371663
    Conditions
    Solid Cancers; NSCLC (Advanced Non-small Cell Lung Cancer); Gastric (Stomach) Cancer; Endometrial Cancer; Malignant Melanoma
    Interventions
    TCC1727 tablet 90mg; TCC1727 tablet 120mg; TCC1727 tablet 160mg; benmelstobart Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-12-03
    Completion
    2029-06-30
    Enrolment
    266

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Cancers; NSCLC (Advanced Non-small Cell Lung Cancer); Gastric (Stomach) Cancer; Endometrial Cancer +1 more
    InterventionTCC1727 tablet 90mg; TCC1727 tablet 120mg; TCC1727 tablet 160mg; benmelstobart Injection
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

    NCT05092360 · start 2022-01-10

    Registered record
    Registry ID
    NCT05092360
    Conditions
    Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
    Interventions
    Nemvaleukin and Pembrolizumab Combination; Pembrolizumab; Nemvaleukin; Pegylated Liposomal Doxorubicin (PLD); Paclitaxel; Topotecan; Gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2022-01-10
    Completion
    2025-05-08
    Enrolment
    456

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlatinum-resistant Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
    InterventionNemvaleukin and Pembrolizumab Combination; Pembrolizumab; Nemvaleukin; Pegylated Liposomal Doxorubicin (PLD) +3 more
    PhasePhase 3
    Registry statusTerminated

  • A Study of N9 Chemotherapy in Children With Neuroblastoma

    NCT04947501 · start 2021-06-22

    Registered record
    Registry ID
    NCT04947501
    Conditions
    Neuroblastoma; Pediatric Cancer
    Interventions
    Cyclophosphamide; Topotecan; Vincristine; Doxorubicin; Ifosfamide; Etoposide; Carboplatin; Mesna
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Active not recruiting
    Start
    2021-06-22
    Completion
    2027-06-22
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroblastoma; Pediatric Cancer
    InterventionCyclophosphamide; Topotecan; Vincristine; Doxorubicin +4 more
    PhaseEarly phase 1
    Registry statusActive not recruiting

  • A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

    NCT04908787 · start 2021-06-11

    Registered record
    Registry ID
    NCT04908787
    Conditions
    Ovarian Cancer
    Interventions
    BD0801; Paclitaxel; Placebo; Topotecan; doxorubicin liposome
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-06-11
    Completion
    2024-10-11
    Enrolment
    421

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    InterventionBD0801; Paclitaxel; Placebo; Topotecan +1 more
    PhasePhase 3
    Registry statusCompleted

  • Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

    NCT04768296 · start 2021-03-29

    Registered record
    Registry ID
    NCT04768296
    Conditions
    Small-cell Lung Cancer
    Interventions
    Berzosertib; Berzosertib; Topotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-03-29
    Completion
    2023-07-21
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall-cell Lung Cancer
    InterventionBerzosertib; Berzosertib; Topotecan
    PhasePhase 2
    Registry statusCompleted

  • Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

    NCT04679064 · start 2020-12-01

    Registered record
    Registry ID
    NCT04679064
    Conditions
    Ovarian Cancer
    Interventions
    Niraparib; Dostarlimab; Pegylated liposomal doxorubicin; Paclitaxel; Gemcitabine; Topotecan; Bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-12-01
    Completion
    2025-01-01
    Enrolment
    427

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    InterventionNiraparib; Dostarlimab; Pegylated liposomal doxorubicin; Paclitaxel +3 more
    PhasePhase 3
    Registry statusUnknown

  • Efficacy of Letrozole in Recurrent Ovarian Cancer

    NCT04421547 · start 2020-06-22

    Registered record
    Registry ID
    NCT04421547
    Conditions
    Epithelial Ovarian Cancer
    Interventions
    Letrozole 2.5mg; Standard single agent chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2020-06-22
    Completion
    2024-11-04
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpithelial Ovarian Cancer
    InterventionLetrozole 2.5mg; Standard single agent chemotherapy
    PhasePhase 3
    Registry statusTerminated

  • Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

    NCT03896503 · start 2019-12-30

    Registered record
    Registry ID
    NCT03896503
    Conditions
    Extensive Stage Lung Small Cell Carcinoma; Extrapulmonary Small Cell Neuroendocrine Carcinoma; Limited Stage Lung Small Cell Carcinoma; Platinum-Resistant Lung Small Cell Carcinoma; Platinum-Sensitive Lung Small Cell Carcinoma; Recurrent Lung Small Cell Carcinoma
    Interventions
    Berzosertib; Biopsy Procedure; Biospecimen Collection; Computed Tomography; Topotecan Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-12-30
    Completion
    2027-05-13
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtensive Stage Lung Small Cell Carcinoma; Extrapulmonary Small Cell Neuroendocrine Carcinoma; Limited Stage Lung Small Cell Carcinoma; Platinum-Resistant Lung Small Cell Carcinoma +2 more
    InterventionBerzosertib; Biopsy Procedure; Biospecimen Collection; Computed Tomography +1 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer

    NCT03632798 · start 2018-08-01

    Registered record
    Registry ID
    NCT03632798
    Conditions
    Recurrent Ovarian Cancer
    Interventions
    ChemoID assay; Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2018-08-01
    Completion
    2019-06-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Ovarian Cancer
    InterventionChemoID assay; Chemotherapy
    PhasePhase 3
    Registry statusWithdrawn

  • Chronic Convection Enhanced Delivery of Topotecan

    NCT03154996 · start 2018-01-18

    Registered record
    Registry ID
    NCT03154996
    Conditions
    Gliomas
    Interventions
    Topotecan; Gadolinium; Synchromed II infusion pumps
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-01-18
    Completion
    2021-08-20
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGliomas
    InterventionTopotecan; Gadolinium; Synchromed II infusion pumps
    PhasePhase 1
    Registry statusCompleted